Thursday, December 06, 2018 7:31:50 PM
To bring about this vision, Biotricity has built a platform for both diagnostic monitoring and post-diagnostic chronic care solutions. Biotricity’s platform is comprised of three key components: an IoT hardware with built-in cellular connectivity, an embedded Real Time Operating System (RTOS), and the cloud for analysis and management of both data and devices.
Our flagship product, the Bioflux, is the first application of this platform where we have tailored our IoT hardware, RTOS and cloud for the diagnostic cardiac market. The next step is launching our second application, Biolife, that leverages our platform for the post-diagnostic cardiac market. We are committed to applying our platform in new chronic care markets while continuing to develop and advance each component well into the future
Recent BTCY News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 10:02:19 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 10:18:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:55:34 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:15:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/19/2023 08:57:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 12:38:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:26:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:14:24 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 07/17/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 08:05:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 09:29:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM